Quest Diagnostics To Speak At JPMorgan H&Q Healthcare Conference

Quest Diagnostics Incorporated , the nation's leading provider of diagnostic testing, information and services, announced that Kenneth W. Freeman, Chairman and Chief Executive Officer, is scheduled to speak at the JPMorgan H&Q 20th Annual Healthcare Conference on Tuesday, January 8, 2002, at the Westin St. Francis Hotel in San Francisco. The Quest Diagnostics presentation is scheduled to begin at 8:30 a.m. Pacific Time. The conference is being webcast live and can be accessed on the Internet at: A replay of the webcast will be available for 60 days following the conference.

Quest Diagnostics is scheduled to release financial results for the fourth quarter ended December 31, 2001, after the close of the stock market on January 28, 2002. The company is currently in a "quiet" period and is scheduled to discuss results for the fourth quarter during a conference call on January 29 at 8:00 a.m. Eastern Time. To hear a simulcast of the call over the Internet or a replay, registered analysts may access StreetEvents at:; and all others may access the Quest Diagnostics website at: In addition, a replay of the call will be available from 10 a.m. on January 29 through 5 p.m. on January 31 to investors in the U.S. by dialing 800-754-7906. Investors outside the U.S. may dial 402-220-0366. No password is required for either number.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with $3.4 billion in annual revenues. The company's diagnostic testing yields information that enables health care professionals and consumers to make better decisions to improve health. Quest Diagnostics offers patients and physicians the broadest access to diagnostic testing services through its national network of approximately 30 full-service laboratories, 150 rapid response laboratories and more than 1,300 patient service centers, where specimens are collected. Quest Diagnostics is the leading provider of esoteric testing, including gene-based testing, and is the leader in routine medical testing, drugs of abuse testing, and non-hospital-based anatomic pathology testing. Quest Diagnostics empowers health care organizations and clinicians with state-of-the-art connectivity solutions that improve practice management. Through partnerships with pharmaceutical, biotechnology and information technology companies, Quest Diagnostics provides support to help speed the development of health care insights and new therapeutics. Additional company information can be found on the Internet at:

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 2000 Form 10-K and subsequent filings.


SOURCE: Quest Diagnostics Incorporated

Contact: Media - Gary Samuels, +1-201-393-5700, Investors - Cathy
Doherty, +1-201-393-5030, both of Quest Diagnostics Incorporated